These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
632 related articles for article (PubMed ID: 34016182)
1. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182 [TBL] [Abstract][Full Text] [Related]
2. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995 [TBL] [Abstract][Full Text] [Related]
3. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA. Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100 [TBL] [Abstract][Full Text] [Related]
4. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887 [TBL] [Abstract][Full Text] [Related]
5. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187 [TBL] [Abstract][Full Text] [Related]
6. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750 [TBL] [Abstract][Full Text] [Related]
7. The dynamic range of circulating tumor DNA in metastatic breast cancer. Heidary M; Auer M; Ulz P; Heitzer E; Petru E; Gasch C; Riethdorf S; Mauermann O; Lafer I; Pristauz G; Lax S; Pantel K; Geigl JB; Speicher MR Breast Cancer Res; 2014 Aug; 16(4):421. PubMed ID: 25107527 [TBL] [Abstract][Full Text] [Related]
8. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma. Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284 [TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. Pagès M; Rotem D; Gydush G; Reed S; Rhoades J; Ha G; Lo C; Fleharty M; Duran M; Jones R; Becker S; Haller M; Sinai CE; Goumnerova L; Golub TR; Love JC; Ligon KL; Wright KD; Adalsteinsson VA; Beroukhim R; Bandopadhayay P Neuro Oncol; 2022 Aug; 24(8):1352-1363. PubMed ID: 34984433 [TBL] [Abstract][Full Text] [Related]
10. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Chin YM; Shibayama T; Chan HT; Otaki M; Hara F; Kobayashi T; Kobayashi K; Hosonaga M; Fukada I; Inagaki L; Ono M; Ito Y; Takahashi S; Ohno S; Ueno T; Nakamura Y; Low SK Cancer Sci; 2022 May; 113(5):1808-1820. PubMed ID: 35201661 [TBL] [Abstract][Full Text] [Related]
11. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406 [TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634 [TBL] [Abstract][Full Text] [Related]
13. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984 [TBL] [Abstract][Full Text] [Related]
14. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920 [TBL] [Abstract][Full Text] [Related]
15. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection. Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317 [TBL] [Abstract][Full Text] [Related]
16. Targeted mutation detection in breast cancer using MammaSeq™. Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836 [TBL] [Abstract][Full Text] [Related]
17. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639 [TBL] [Abstract][Full Text] [Related]
18. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761 [TBL] [Abstract][Full Text] [Related]
19. Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy. Li L; Wang Y; Shi W; Zhu M; Liu Z; Luo N; Zeng Y; He Y Cancer Med; 2019 Dec; 8(18):7669-7678. PubMed ID: 31692284 [TBL] [Abstract][Full Text] [Related]
20. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]